CD

Calliope Dendrou

Kennedy Institute of Rheumatology, Reuben College, University of Oxford, University of Cambridge, Imperial College London, Centre for Human Genetics

Research areas: Biochemistry, Genetics and Molecular Biology · Molecular Biology · Single-cell and spatial transcriptomics · Genetic Associations and Epidemiology · T-cell and B-cell Immunology

ORCID iD 0000-0003-1179-4021

About

Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR) where she leads the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship to start her group in 2017 at the Centre for Human Genetics in Oxford, where she was also the Equality, Diversity and Inclusion Champion, before moving to the KIR in 2023. Calli’s research focuses on investigating shared molecular circuits and cellular mechanisms across tissues and across immune-mediated diseases. Her group uses high-resolution genomic profiling technologies to help elucidate cross-disease pathophysiology, particularly as pathological drivers may evolve over time and may change due to environmental influences and therapeutic intervention. Her research aims to identify ‘hubs’ that may be targeted therapeutically via drug repositioning approaches, with an especial emphasis on cytokine signalling pathways. She is also the Data Analysis Lead for several large-scale collaborative projects including the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative LEGACY Network, and enjoys teaching on the MSc in Genomic Medicine programme, as the ‘Single-Cell & Spatial Omics for Precision Medicine’ Module Lead.

Employment

Education

Projects & Funding

  • Stop the clock on chronic inflammation Wellcome Trust Ltd
    2026 - 2034
  • Establishing biomarkers to predict patient drug response in inflammatory bowel disease Medical and Life Sciences Translational Fund
    2025 - 2026
  • Fibrosis Unmasked: A Metabolic Cell Odyssey Across Tissues and Diseases Novo Nordisk (Denmark)
    2025 - 2028
  • SAGITTARIUS AbbVie (United States)
    2025 - 2030
  • Oxford-GSK Alliance Experimental Medicine Centre GlaxoSmithKline (United Kingdom)
    2025 - 2030
  • Lymph nodE single cell Genomics AnCestrY immunity, infection, inflammation and immunisation (LEGACY IIII) Network Medical Research Council
    2025 - 2029
  • MRC CoRE in Exposome Immunology Medical Research Council
    2025 - 2032
  • Cartography 3.0 Johnson & Johnson (United States)
    2024 - 2027
  • Identification of antigens targeted by T-cells mediating GvL & GvHD following Stem Cell Transplant CRUK
    2024 - 2029
  • Phase 1a, Multi Centre Vaccine Trial of VAC096 and Associated Immunology Bill and Melinda Gates Foundation
    2023 - 2027
  • The case for a Childhood Therapeutic Atlas Chan Zuckerberg Initiative (United States)
    2023 - 2026
  • Lymph Node Single-Cell Genomics Ancestry (LEGACY) Network Chan Zuckerberg Initiative (United States)
    2022 - 2026
  • Tissue research in childhood inflammatory arthritis (TRICIA consortium) Medical Research Council
    2022 - 2027
  • Cartography 2.0 Janssen Inc.
    2022 - 2024
  • Precision genome editing with tandem autologous transplantation as a therapy for multiple severe immune-mediated diseases Medical Research Council
    2021 - 2023
  • Cartography 1.0 Janssen Inc.
    2021 - 2023
  • Mapping human inflammatory response kinetics in ethnically diverse groups Chan Zuckerberg Initiative (United States)
    2019 - 2023
  • An Extended Pilot for the Human Cell Atlas: Adult tissues, human development and inflammation-mediated pathologies Wellcome
    2018 - 2022
  • Therapeutically mimicking SNPs Nimbus Therapeutics
    2018 - 2022
  • Tyrosine kinase 2: A genetically determined drug target for multiple autoimmune diseases Rosetrees Trust
    2018 - 2022
  • Human Immune Discovery Initiative Genomics platform NIHR Oxford Biomedical Research Centre
    2018 - 2020
  • Investigating the functional basis of shared genetic etiology across autoimmune diseases Wellcome Trust Ltd
    2017 - 2024
  • Studying the effects of pregnancy in MS Aims2Cure
    2016 - 2019
  • Translating Big Data Into New Treatments Frances and Augustus Newman Foundation
    2015 - 2018
  • Functional immunogenetics of neurodegeneration Takeda Pharmaceutical Company
    2015 - 2018
  • The International Neuromyelitis Optica Genetics Consortium Guthy-Jackson Charitable Foundation
    2015 - 2017
  • A genetically-determined drug target for MS Rosetrees Trust
    2014 - 2017
  • MS genetics: informing clinical practice Rosetrees Trust
    2012 - 2014
  • CD25, a type 1 diabetes gene encoding the alpha chain of the interleukin-2 receptor: cellular phenotypes assocaited with susceptibility and resistance genotypes. Wellcome Trust
    2005 - 2009

Publications (69)